Influenza vaccine production constraints caused by increased production of COVID-19 vaccines
First written in FY2022-Q2. 1 of 3 entries say "Restated". Latest entry: FY2023-Q2.
No other company in this theme has enough history to compare yet.
- FY2023-Q2MitigatedAnnual report
「Influenza vaccine shipments exceeded the previous year because production capacity had been expanded.」
Shipments exceeded the previous year as production capacity was expanded, addressing the previous constraints on influenza vaccine production and shipments caused by shortages of materials associated with increased COVID-19 vaccine production, among other factors. - FY2022-Q3RestatedAnnual report
「Influenza vaccine shipments were below the previous year because production volumes fell below the previous year, owing to the effects of factors including the growth characteristics of the vaccine production strain, in addition to shortages of production materials caused by the global increase in production of novel coronavirus vaccines.」
The company has reconfirmed constraints on influenza vaccine production and shipments caused by shortages of materials associated with increased COVID-19 vaccine production, among other factors. - FY2022-Q2First statedAnnual report
「Influenza vaccine shipments were below the previous year because production volumes fell below the previous year, owing to the effects of factors including the growth characteristics of the vaccine production strain, in addition to shortages of production materials caused by the global increase in production of novel coronavirus vaccines.」
It states that influenza vaccine production volumes and shipments fell below the previous year due to shortages of production materials associated with the global increase in COVID-19 vaccine production, as well as the growth characteristics of vaccine production strains.